Opiant Pharmaceuticals (OPNT) Downgraded by TheStreet
Separately, ValuEngine lowered Opiant Pharmaceuticals from a strong-buy rating to a buy rating in a report on Monday, October 2nd.
Opiant Pharmaceuticals (NASDAQ OPNT) opened at $23.50 on Monday. The company has a market capitalization of $49.86, a price-to-earnings ratio of 57.40 and a beta of -2.33. Opiant Pharmaceuticals has a fifty-two week low of $5.00 and a fifty-two week high of $51.90.
In related news, major shareholder Geoffrey Wolf sold 2,570 shares of Opiant Pharmaceuticals stock in a transaction dated Friday, December 8th. The stock was sold at an average price of $30.40, for a total transaction of $78,128.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 63.82% of the stock is owned by insiders.
Opiant Pharmaceuticals Company Profile
Opiant Pharmaceuticals, Inc, formerly Lightlake Therapeutics, Inc, is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).
Receive News & Stock Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related stocks with our FREE daily email newsletter.